0.05Open0.05Pre Close0 Volume50 Open Interest1.00Strike Price0.00Turnover405.36%IV39.87%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.1125Delta0.2587Gamma31.60Leverage Ratio-0.0145Theta0.0000Rho-3.55Eff Leverage0.0003Vega
Regulus Therapeutics Stock Discussion
📊⚡️📊
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vanguard loaded
Regulus Therapeutics Inc., a biopharmaceutical company listed on Nasdaq under the ticker symbol RGLS, has recently announced positive topline results from the third cohort of patients in its Phase 1b Multiple-Ascending Dose (MAD) clinical trial of RGLS8429. This investigational drug is being developed for the treatment of ...
No comment yet